This article is more than 5 years old. Information may no longer be current.
Janssen, Protagonist enter agreement for IL-23 IBD candidate
Click Here to Manage Email Alerts
Janssen Biotech, Inc. announced its exclusive licensing and collaboration agreement on PTG-200, an oral interleukin-23 receptor antagonist currently under development with Protagonist Therapeutics to treat Crohn’s disease and ulcerative colitis.
“We look to continue to pioneer the science of inflammatory bowel disease and advance novel therapeutics like PTG-200, an oral therapy that targets a validated pathway and acts locally in the gut at the site of disease,” Scott E. Plevy, MD, vice president, disease area leader, inflammatory bowel disease, Janssen, said in the press release. “We’re particularly excited to add an oral peptide-based therapy to our robust portfolio as we aim to address the increasing incidence of inflammatory bowel disease and the growing needs of people living with Crohn’s disease and ulcerative colitis around the world.”
Investigational new drug studies are ongoing for PTG-200 and phase 1 trials should begin this year, according to the release. Protagonist will receive an upfront payment and will be eligible for milestone payments along the development and commercialization process. Once commercialized, Protagonist may receive royalties and will have the option to co-detail within the U.S., according to the release. This transaction is projected to close in the third quarter of 2017.
“The addition of PTG-200 to the Janssen Immunology portfolio builds upon our expertise and leadership in the IL-23 pathway and we look forward to advancing this novel oral IL-23 [receptor] antagonist into clinical development,” Susan B. Dillon, PhD, global therapeutic area head, immunology, Janssen, said in the release.
Disclosures: Dillon and Plevy are employed by Janssen.